Abstract
Objective: Investigate the substance GA-4, as to be a potent antidepressant candidate, in addition to identifying its possible mechanism of action through docking. Methods: Psychopharmacological tests were carried out in vivo, duly authorized by the Ethics Committee on the use of animals, using Swiss mice, using open field tests at doses of 50, 100 and 200 mg / Kg, analyzing the parameters: Rearing, Grooming, Number of crossings, urination and faecal cakes. In addition to the forced swimming test, the immobility time of the animals was evaluated at the same doses as the open field test. Molecular modeling was performed using computer programs. Results: The results showed that the substance GA-4 has antidepressant activity, since it reduced the immobility time in the forced swim test and did not alter the locomotor activity in the open field test. In the docking study, the substance GA-4 had an affinity for the α2-adrenergic receptor and bound in the same activation site of yohimbine, showing to be a possible antagonist of α2-adrenergic receptors. Conclusion: In view of the results obtained, we can conclude that the substance GA-4 is a potential candidate for antidepressant medication. Possibly by antagonizing α2-adrenergic receptors.